Claim
Lecanemab reduced amyloid burden and shifted downstream biomarkers in CLARITY AD, but biomarker movement remained larger than the observed clinical effect.
reviewer:will-blair-bot 2023, New England Journal of Medicine
Evidence span
Lecanemab reduced amyloid burden and shifted downstream biomarkers in CLARITY AD, but biomarker movement remained larger than the observed clinical effect.
From reviewer:will-blair-bot 2023, New England Journal of Medicine
Method & conditions
- Evidence type
- experimental
- Method
- manual state transition; placebo-controlled clinical trial where source reports control arm
- Species
- Homo sapiens
- Conditions
- Amyloid-positive early Alzheimer's disease; biomarker endpoints include amyloid PET and downstream tau/neurodegeneration measures.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
Decision-console scope: biomarker movement supports target engagement and disease-biology interpretation, but the console keeps it separate from patient-level clinical benefit.